1. India Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Vivo Bio Tech Ltd.

Vivo Bio Tech Ltd.

13.02
INR
-1.32
(-9.21%)
-1.34EPS
530.13MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
17.25
19.02
30.57
36.5
47.71
53.78
43
38.58
36.34
35.23
30.5
30.52
25.67
25.77
Basic EPS, GAAP
0.31
0.49
0.97
2.68
3.17
2.17
3.45
4.23
1.56
1.79
1.7
4.76
-0.82
-1.34
Free Cash Flow per Basic Share
1.46
0.22
1.73
-18.71
6.49
-4.15
-1.26
-6.44
-24.38
7.31
5.08
-6.83
-1.21
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
9.12
9.81
10.76
13.45
19.6
22.08
25.62
31.69
33.04
34.81
36.5
45.39
41.98
- -
Tangible Book Value per Share
3.05
4.57
3.91
7.53
13.15
17.87
20.68
23.25
23.49
27.56
31.05
31.49
18.9
- -
Basic Weighted Avg Shares
9
9
9
9
10
10
13
13
14
15
15
15
21
21
Sales/Revenue/Turnover
161
178
286
341
470
558
554
518
514
522
455
467
533
551
Operating Margin (%)
2.35
0.01
2.26
10.93
18.06
20.03
28.01
23.55
17.01
24.07
26.38
24.73
20.41
17.24
Depreciation Expense
16
30
34
39
46
51
52
56
74
93
93
90
106
115
Net Income, GAAP
3
5
9
25
31
22
44
57
22
26
25
73
-17
-29
Effective Tax Rate (%)
56.62
- -
- -
11.69
22.09
- -
- -
34.08
50.77
42.67
37.78
17.18
135.53
177.91
Profit Margin (%)
1.82
2.6
3.18
7.33
6.64
4.03
8.02
10.97
4.28
5.07
5.56
15.6
-3.2
-5.19
Working Capital
-70
-67
-102
30
24
61
64
52
29
68
93
141
-18
- -
LT Debt
35
27
23
209
139
89
97
146
501
431
418
349
466
- -
Total Equity
85
92
101
126
193
273
330
425
471
519
544
779
932
- -
Return on Invested Capital (%)
1.22
- -
- -
12.01
11.62
- -
- -
12.16
4.53
6.25
6.1
10.14
-2.45
- -
Return on Capital (%)
3.44
- -
- -
13.28
11.81
- -
- -
12.24
4.43
6.15
6.09
10.41
-2.59
- -
Return on Common Equity (%)
3.5
5.23
9.44
22.11
19.58
9.65
14.73
15.04
4.91
5.35
4.75
11.01
-2
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
208
- -
LT Borrowings
- -
466
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
22
22
22
Market Capitalization
698
467
530

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
284
- -
Cash, Cash Equivalents & STI
- -
14
- -
Accounts Receivable, Net
- -
117
- -
Inventories
- -
82
- -
Total Current Liabilities
- -
302
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
208
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
25.82%
17.71%
19.58%
Free Cash Flow
-129.42%
-35.36%
-76%
Net Income, GAAP
31.7%
3.85%
-123.46%
Sales/Revenue/Turnover
7.35%
0.97%
14.27%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
101
120
122
123
467
2026
125
131
135
142
533
2027
143
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.11
3.51
0.55
0.69
4.76
2026
0.74
0.45
0.56
-2.52
-0.82
2027
0.08
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Alangudi Sankaranarayanan
Full Time Employees
247
Sector
Distribution services
Industry
Medical distributors
Address
Ilyas Mohammed Khan Est, #8-2-672 Hyderabad TS India 500034
IPO Date
May 23, 1994
Website
vivobio.com
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Vivo Bio Tech Limited (VIVOBIOT.BO) is an India-based biotechnology company that engages in contract research and manufacturing services for pharmaceutical and agrochemical industries. The company offers a range of services including custom synthesis of advanced intermediates and active pharmaceutical ingredients (APIs), process research and development, scale-up manufacturing, and analytical method development; it specializes in complex multi-step organic synthesis, handling hazardous reactions, and producing high-purity compounds under cGMP conditions. Its product portfolio encompasses key starting materials, building blocks, and reference standards for drug discovery and development, primarily serving global pharmaceutical companies, contract development and manufacturing organizations (CDMOs), and research institutions. Founded in 2007 and headquartered in Hyderabad, India, Vivo Bio Tech operates primarily from its manufacturing facilities in India, with exports to North America, Europe, and Asia. In recent developments, the company has focused on capacity expansion through investments in new production lines for API manufacturing and strengthened its quality compliance to meet USFDA standards, enabling entry into regulated markets; it reported revenue growth from increased contract orders in 2024-2025 amid rising demand for outsourced R&D services.